The company has ditched a trial of drebuxelimab plus ivonescimab.
ApexOnco Front Page
Recent articles
CRB-601 and PF-06940434 fall by the wayside.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
A newly published cache of CRLs includes six novel oncology drugs.
The deal for ISB 2001 is worth $700m up front.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
